A true cure for herpes doesn’t exist yet, but the science is closer than it has ever been. Gene-editing therapies have eliminated up to 97% of latent herpes virus in animal studies, therapeutic vaccines are in clinical trials, and a gene therapy for herpes-related eye disease is already in Phase 2 testing in humans. None of these are available to patients today, but the field has shifted from managing symptoms to genuinely pursuing a cure.
Why Herpes Is So Hard to Cure
Herpes simplex virus, both type 1 and type 2, uses a survival strategy that makes it uniquely difficult to eliminate. After the initial infection, the virus travels into nerve cells and goes dormant. During this latent phase, it produces no infectious virus, causes no symptoms, and is essentially invisible to the immune system. The viral DNA sits quietly inside neurons, with all of its active genes switched off.
The only thing the virus produces while hiding are small RNA molecules called latency-associated transcripts. These tiny gene products don’t code for proteins, which means the immune system has nothing to recognize or attack. Some of these RNA molecules actively suppress the virus’s own genes, keeping it in its dormant state until conditions favor reactivation. The virus also wraps its DNA in chemical tags that silence gene expression, using the cell’s own machinery against it.
When the virus does reactivate, it has another trick. It produces a protein that blocks infected cells from displaying viral fragments on their surface. Normally, immune cells called CD8+ T cells patrol the body looking for these surface signals. By disabling that display system, herpes buys itself time to replicate and spread before the immune response catches up. Some CD8+ T cells do camp out near the nerve clusters where the virus hides and can halt reactivation through non-destructive mechanisms, but they can’t clear the infection entirely.
This is the core problem: antiviral medications like valacyclovir work by disrupting viral replication, but they can’t touch a virus that isn’t replicating. As long as dormant viral DNA remains inside neurons, the infection persists.
Gene Editing: The Closest Thing to a Cure
The most promising cure research comes from gene-editing approaches that go after dormant viral DNA directly, something no existing drug can do.
A team at Fred Hutchinson Cancer Center has developed a method using engineered enzymes called meganucleases, delivered into nerve cells by harmless viral carriers. In mouse models, this approach eliminated 90% or more of latent HSV-1 DNA in facial infection models and up to 97% in genital infection models. The reductions were dose-dependent: higher doses cleared more virus. At the highest doses tested, viral shedding dropped by 97 to 100% after treatment, published in Nature Communications in 2024.
Those numbers are striking, but the researchers themselves note that the relevance for human infection is still uncertain. Mouse nervous systems are far simpler than human ones, and the virus may distribute differently across human nerve clusters. Scaling the delivery of gene-editing tools to reach all the neurons harboring virus in a human body remains a major engineering challenge.
A separate effort from Excision BioTherapeutics is developing a CRISPR-based therapy called EBT-104 for herpes. It’s still in preclinical development, with early lab data released in mid-2024. Meanwhile, a Chinese company called BDGene is already running a Phase 2 trial of a gene-editing treatment called BD111 for herpes-related eye infections (stromal keratitis). That trial is testing whether a single injection into the cornea can clear HSV-1 DNA and prevent recurrence over 12 months. It’s a narrower application than a systemic cure, but it’s the first gene-editing herpes therapy being tested in humans.
Therapeutic Vaccines in Clinical Trials
A different strategy aims not to eliminate the virus but to train the immune system to suppress it so effectively that outbreaks stop and transmission becomes unlikely. These therapeutic vaccines are designed for people who already have herpes, unlike preventive vaccines given before infection.
Moderna completed a clinical trial of mRNA-1608, an mRNA-based therapeutic vaccine for genital HSV-2, in April 2025. The trial enrolled healthy adults aged 18 to 55 with recurrent genital herpes. Results from this trial have not yet been published, but the fact that a major vaccine manufacturer is investing in herpes therapeutics signals serious commercial and scientific interest.
Live-attenuated vaccine candidates are also in development. These use weakened versions of the virus itself to provoke a stronger, broader immune response than subunit vaccines that contain only isolated viral proteins. In animal studies, candidates like VC2 (for HSV-1) and 0ΔNLS (for HSV-2) generated robust immune responses, including strong neutralizing antibodies and durable memory T cell populations. Vaccinated animals showed suppressed viral shedding, reduced latency, and in eye infection models, completely preserved visual acuity. The concept mirrors the highly successful chickenpox vaccine, which targets a closely related herpesvirus that also hides in neurons. These candidates still need Phase 1 and Phase 2 human trials.
Better Antivirals Are Coming, Too
Even if a true cure takes years, the next generation of antiviral drugs represents a meaningful step forward. Pritelivir works through a completely different mechanism than current medications. Instead of targeting the enzyme that copies viral DNA (how valacyclovir and acyclovir work), it blocks the machinery that unwinds DNA before copying begins.
In a randomized clinical trial published in JAMA, pritelivir cut the number of days with detectable viral shedding roughly in half compared to valacyclovir, with 173 positive swab samples during pritelivir treatment versus 392 during valacyclovir treatment. It also reduced lesion frequency and shedding episode duration. This matters because even on current antivirals, protection against transmission is only about 50%, largely because these drugs don’t fully suppress viral shedding. Pritelivir isn’t a cure, but it could substantially reduce both symptoms and transmission risk.
The Scale of the Problem
The World Health Organization estimates that roughly 846 million people between ages 15 and 49 are living with genital herpes infections globally, more than one in five adults in that age range. Of those, about 520 million have HSV-2, and around 376 million have genital HSV-1 infections (with 50 million carrying both types simultaneously). These figures, based on 2020 data and released in late 2024, underscore why so many research groups and pharmaceutical companies are pursuing treatments. The sheer prevalence means even incremental progress affects hundreds of millions of people.
A Realistic Timeline
The honest answer is that a widely available cure is likely still a decade or more away, but the path there is more concrete than it has ever been. Gene-editing therapies need to prove they can safely reach enough neurons in a human nervous system to make a clinical difference. Therapeutic vaccines need to demonstrate that immune boosting alone can meaningfully change the course of infection. Both approaches are being actively tested.
The most likely near-term scenario is a layered one: better antivirals like pritelivir reducing viral activity, therapeutic vaccines strengthening immune control, and eventually gene-editing tools eliminating the dormant reservoir. Each of these alone would improve life with herpes. Together, they could functionally cure it, meaning the virus is either gone or suppressed so thoroughly that it never reactivates or transmits. For the first time, the biological obstacles that have made herpes a lifelong infection are being directly targeted rather than worked around.